Regulation of endothelin‐1 and transforming growth factor‐β1 production in cultured proximal tubular cells by albumin and heparan sulphate glycosaminoglycans

Fine LG, Ong AC, Norman JT. Mechanisms of tubulointerstitial injury in progressive renal disease. Eur J Clin Invest1993; 23: 359–365

Diaz FJ. Vasoactive hormones and renal sclerosis. Kidney Int1996; 49: 578–597

Yanagisawa BD, Kurihara H, Kimura S. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature1988; 332: 411–415

Wilkes BM, Susin M, Mento PF. Localization of endothelin‐like immunoreactivity in rat kidneys. Am J Physiol1991; 260: F913–920

Battistini B, Chailer P, D'orleans‐Juste P, Briere N, Sirois P. Growth regulatory property of endothelins. Peptides1993; 14: 385–399

Helset E, Sildnes T, Seljelid R, Konopski ZS. Endothelin‐1 stimulates human monocytes in vitro to release TNF‐α, IL‐1β and IL‐6. Mediat Inflam1993; 2: 417–422

Hocher B, Thöne‐Reineke C, Rohmeis P et al. Endothelin‐1 transgenic mice develop glomerulosclerosis, interstitial fibrosis and renal cysts but not hypertension. J Clin Invest1997; 99: 1380–1389

Bertelli R, Valenti F, Oleggini R et al. Cell‐specific regulation of alpha 1(III) and alpha 2 (V) collagen by TGF‐beta1 in tubulointerstitial cell models. Nephrol Dial Transplant1998; 13: 573–579

Fishberg Y, Kelly CJ. TGF‐beta and regulation of interstitial nephritis. Miner Electrolyte Metab1998; 24: 181–189

Zoja C, Morigi M, Figliuzzi M et al. Proximal tubular cell synthesis of endothelin 1 in challenge with albumin and other proteins. Am J Kidney Dis1995; 26: 934–941

Floege J, Eng E, Young BA, Johnson RJ. Heparin suppresses mesangial cell proliferation and matrix expansion in experimental mesangioproliferative glomerulonephritis. Kidney Int1993; 43: 369–380

Van der Woude FJ, van Det N. Heparan sulfate proteoglycans in diabetic nephropathy. Exp Nephrol1997; 5: 180–188

Rusnati M, Coltrini D, Caccia P et al. Distinct role of 2‐O‐, N‐ and 6‐O‐sulphate groups of heparin in the formation of the ternary complex with basic fibroblast growth factor and soluble FGF receptor‐1. Biochem Biophys Res Commun1994; 203: 450–458

Camejo EH, Rosengren B, Camejo G, Sartipy P, Fager G, Bondjers G. IFN‐gamma binds to extracellular matrix chondroitin‐sulfate proteoglycans, thus enhancing its cellular response. Arterioscler Thromb Vasc Res1995; 15: 1456–1465

Ong ACM. Tubulointerstitial actions of endothelins in the kidney: roles in health and disease. Nephrol Dial Transplant1996; 11: 251–257

Achmad T, Rao G. Chemotaxis of human blood monocytes toward endothelin‐1 and the influence of calcium channel blockers. Biochem Biophys Res Commun1992; 189: 994–1000

McCaffrey TA, Falcone DJ, Vincente D, Du B, Consigli S, Borth W. Protection of transforming growth factor‐beta 1 activity by heparin and fucoidin. J Cell Physiol1994; 159: 51–59

Lyon M, Rushton G, Gallagher JT. The interaction of the transforming growth factor‐betas with heparin/heparan sulfate is isoform specific. J Biol Chem1997; 272: 18000–18006

Kohno M, Yokokawa K, Horio T et al. Heparin inhibits endothelin‐1 production in rat cultured mesangial cells. Kidney Int1994; 45: 137–142

Yokokawa K, Kohno M, Mandal AK, Tahara H, Yanagisawa M, Takeda T. Heparin suppressed endothelin‐1 peptide and mRNA expression in cultured endothelial cells of spontaneously hypertensive rats. JASN1994; 4: 1683–1689